Publisher's latest report, Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market provides analysis of the hematological cancers market space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan, including annualized market data from 2015 and forecast to 2022.

The market size for hematological cancers, which covers leukemia, lymphoma and myeloma, is expected to more than double over the forecast period, from $30.7 billion in 2015 to $70.1 billion in 2022, growing at a Compound Annual Growth Rate (CAGR) of 12.5%. The market size in the US is expected to increase at a CAGR of 11.8%, reaching $39.3 billion in 2022, equating to just below half of the global market that year. Although the market will continue to be hit by patent expirations, the approval of new drugs, as well as rising prevalence, will drive market growth

Publisher's latest report Global Non-Hematological Cancers Market to 2021 - Strong Growth Driven by Increased Uptake of Low Toxicity Targeted Treatments and Versatile Biologics provides analysis of the global non-hematological cancers treatment space, specifically breast, colorectal, lung and prostate cancer. It features annualized market data from 2014 and forecast to 2021, as well as details on the current clinical and commercial landscape.

The global treatment market for non-hematological cancers, which includes breast, colorectal, lung and prostate cancers, among others, will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, at a compound annual growth rate (CAGR) of 9.9%. This robust growth will occur in spite of the patent expiries of a number of very commercially successful products, including Avastin, Erbitux and Herceptin. Market drivers will include the increasing prevalence of cancer globally, and the introduction of more targeted treatments.